 .alpha.-.beta. C4BP-type recombinant heteromultimeric proteins |
| The object of the present invention is therefore to develop recombinant soluble heteromultimeric ... |
|
| Semi-refined carrageenan |
| The present invention provides methods for preparing a carrageenan product comprising the steps of ... |
|
| Method for improving genetic stability of foreign insert nucleotide sequence in recombinant poliovirus |
| To be free from shortcomings of the poliovirus vector systems, in particular, genetic instability ... |
|
| Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| The invention relates to adult dedifferentiated programmable stem cells derived from human ... |
|
| Peptides which enhance transport across tissues and methods of identifying and using the same |
| The invention provides a method of identifying a peptide which permits or facilitates the transport ... |
|
| Synthetic peptides and kits for diagnosis of anti-phospholipid syndrome |
| The invention claimed is: 1. A synthetic peptide selected from the group consisting: (i) a peptide ... |
|
| Synthetic peptide inhibitors of HIV transmission |
| OF THE INVENTION 5.1 DP-178 AND DP-178-LIKE PEPTIDES 5.2 ASSAYS FOR ANTIVIRAL ACTIVITY 5.3 USES OF ... |
|
| Compounds which inhibit HIV replication |
| A first aspect of the present invention is a peptide selected from the group consisting of: (a) the ... |
|
| Hybrid polypeptides with enhanced pharmacokinetic properties |
| OF THE INVENTION Described herein are peptide sequences, referred to as enhancer peptide sequences,... |
|
| 1-aryl-2-hydroxyethyl amides as potassium channel openers |
| OF THE INVENTION The present invention provides novel aryl hydroxyethyl amides and related ... |
|
|
Dermatophagoides nucleic acid molecules, proteins and uses thereof
| Details |
Inventors: McCall, Catherine A.; Hunter, Shirley Wu; Weber, Eric R.;
Assignee: Heska Corporation (Fort Collins, CO)
Primary Examiner: Crouch; Deborah
Assistant Examiner: Woitach; Joseph
Attorney, Agent or Firm: Heska Corporation
The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins. |
|
DETAILED DESCRIPTION OF THE INVENTION The present invention provides for isolated proteins having molecular weights ranging from about 60 kilodaltons (kD) to about 109 kD, that include at least one epitope of a protein allergen of a mite of the genus Dermatophagoides, in particular a mite of the species Dermatophagoides farinae and/or Dermatophagoides pteronyssius.
Such proteins are referred to herein as Der HMW-map proteins.
The present invention further includes methods to isolate and identify nucleic acid molecules encoding Der HMW-map proteins, antibodies directed against Der HMW-map proteins and inhibitors of Der HMW-map protein activity.
As used herein, the term isolated Der HMW-map proteins refers to Der HMW-map proteins derived from Dermatophagoides, and more preferably from Dermatophagoides farinae and/or Dermatophagoides pteronyssius and, as such, can be obtained from its natural source or can be produced using, for example, recombinant nucleic acid technology or chemical synthesis.
Also included in the present invention is the use of this protein and antibodies in a method to detect immunoglobulin that specifically binds to Der HMW-map proteins, to treat pathogenesis against mite allergens, and in other applications, such as those disclosed below.
The products and processes of the present invention are advantageous because they enable the detection of anti-Der HMW-map antibodies in fluids of animals and the inhibition of IgE or Der HMW-map protein activity associated with disease.
One embodiment of the present invention is an isolated Dermatophagoides allergenic composition including: (a) a composition produced by a method comprising: (1) applying soluble proteins of a Dermatophagoides extract to a gel filtration column; (2) collecting excluded protein from the gel filtration column and applying the excluded protein to an anion exchange column; and (3) eluting proteins bound to the anion exchange column with about 0.
3 M Tris-HCl, pH 8 to obtain the Dermatophagoides allergenic composition; and (b) a composition comprising a peptide of a protein produced in accordance with step (a), in which the allergenic composition is capable of a biological function including binding to IgE, stimulating a B lymphocyte response and stimulating a T lymphocyte response
|
|
Drugs 
